Lupus & antiphospholipid syndrome
Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity
Authors' conclusion
This real-world cohort provides clinical and mechanistic evidence that anifrolumab improves clinical outcomes, enables glucocorticoid tapering and reduces LDNs as well as interferon-driven chemokines in patients with active SLE.
Study context
- Population
- Adults with active systemic lupus erythematosus (SLE); active LN or central nervous system involvement excluded
- Participants
- 20 adults
- Outcome
- Mean SLEDAI-2K
- Follow-up
- 12 months
Methodological detailslongitudinal, multicentre, observational, real-world, generalised additive models with patient-level random intercepts
- Longitudinal
- Multicentre
- Observational
- Real-world
- Generalised additive models with patient-level random intercepts
Main finding
As reported in the abstract
Mean SLEDAI-2K at 12 months (baseline 10.9±5.0)
3.1
95% CI 1.1 to 5.1p<0.001
Observational data: associations, not effects.
Further findings
SRI-4 response · month 12
- SRI-4 response rate
- 64.7%
- Intention-to-treat analyses with non-responder imputation
LLDAS and DORIS remission · month 12
- LLDAS reached
- 86%
- DORIS remission achieved
- 50%
PGA · 12 months
- PGA improved from 1.6 to
- 0.2 (95% CI 0.0 to 0.5; p<0.001)
GC use (daily prednisolone equivalents)
- Daily prednisolone equivalents significantly reduced
- P = 0.036
- Dose ≤5 mg/day among patients on GC at baseline
- 11/13
- Discontinued GC
- 3
Drug persistence · 12 months
- Drug persistence
- 65%
Circulating low-density neutrophils (LDNs)
- Circulating LDNs significantly reduced
- P = 0.032
- Interferon-driven chemokines and inflammatory cytokines reduced
Safety
- Adverse events recorded
- 55
- Serious adverse events
- 4
Original publication
Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity. RMD Open. Published 28 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →